ILC2s sensitise pancreatic tumours to PD-1 checkpoint inhibitors in mice
Scientists identify innate lymphoid cells (ILCs) as possible targets for immunotherapies as their activation makes murine pancreatic tumours sensitive to PD-1 checkpoint inhibitors.